Friday, January 18, 2019 7:13:33 AM
Oh, right, Chasing, I forgot about out our trimipramine ANDA. And our generic Adderall tech, which is only shared with a dozen competitors. As a non-delusional investor who prefers fact-based due diligence, I understand that Purdue is much more likely to **SUE** Elite than they are to **BUY** Elite. They already own an antagonist ADF patent, and they get a royalty from Pfizer for every tablet of Embeda sold. Some have argued that is why Pfizer never launched Troxyca, because they would rather see it die on the vine than give Purdue another nickel. Purdue was smart enough to know there were stability problems with the one bead system, and so they never developed it. They did, however, let Alpharma and Pfizer spend millions getting Embeda approved and then successfully sued them as soon as they could. The safest assumption for proper due diligence is that Purdue, a well-known vigorous defender of their patents, is going to sue Elite if the company were to ever get approval for SequestOx. Ignoring this possibility is to ignore reality, and I'm sure Nasrat has considered the cost of a legal battle with Purdue in his decision-making regarding ongoing SequestOx development.
I know what I have here. I have a cGMP and DEA-certified pharmaceutical factory that is currently under utilized. If the company can successfully increase the output of the factory with controlled substances and other high-margin drugs that cannot be manufactured more cheaply overseas, then we could eventually reach profitably in the range of hundreds of millions of dollars and a share price of multiple dollars. I do not fantasize about buyouts from big boys who would rather crush us than own us.
Call on God but row away from the rocks.
-Hunter S. Thompson
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:07:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 08:30:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:55:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 07:21:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:20:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:20:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 12:05:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:58:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:50:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration with ZenaDrone • InvestorsHub NewsWire • 11/16/2023 12:32:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2023 08:15:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 09:30:05 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 07/31/2023 08:20:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2023 08:15:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/29/2023 09:15:09 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/29/2023 08:43:45 PM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM